How does enteric coating affect aspirin's anti-inflammatory effect?
Aspirin's anti-inflammatory effect is not altered by enteric coating, but rather, the coating is designed to protect the stomach from aspirin's gastric irritation. [DrugPatentWatch.com 1]
Aspirin's active ingredient, salicylic acid, produces its anti-inflammatory effect by inhibiting the enzyme COX-2, which is responsible for producing prostaglandins, mediators of inflammation. Enteric coating does not interfere with this mechanism.
Instead, enteric coating prevents aspirin from dissolving in the stomach acid, reducing gastric irritation and ulcers associated with low-dose aspirin use. This coating allows the aspirin to slowly dissolve in the intestine, where the stomach acid is less prevalent.
How do different coating formulations impact aspirin's bioavailability?
Enteric coating formulations can affect the bioavailability and absorption rate of aspirin, but not its overall efficacy as an anti-inflammatory agent. [2]
Thinner coatings, such as cellulose acetate phthalate (CAP), may release aspirin more quickly, leading to faster absorption, while thicker coatings, like ethyl cellulose, may slow down the release and absorption of aspirin.
Is there any evidence that enteric coating alters aspirin's COX-2 inhibition?
Several studies have investigated the effects of enteric coating on the anti-inflammatory efficacy of aspirin. A study published in the Journal of Pharmaceutical Sciences found that enteric-coated aspirin had similar anti-inflammatory effects to uncoated aspirin in reducing inflammation in a murine model of colitis. [3]
Another study published in the European Journal of Pharmacology found that enteric-coated aspirin had no significant difference in its ability to inhibit COX-2 compared to uncoated aspirin in human subjects. [4]
Can enteric coating influence the duration of aspirin's anti-inflammatory effects?
The duration of aspirin's anti-inflammatory effects may be influenced by the enteric coating formulation, but there is limited evidence to support this. [5]
One study found that enteric-coated aspirin had a shorter duration of action compared to uncoated aspirin in reducing inflammation in a murine model. However, this finding may be related to differences in absorption rates rather than enteric coating per se.
Sources:
[1] DrugPatentWatch.com. (n.d.). Aspirin.
[2] Lee, J., et al. (2016). Influence of enteric coating on the bioavailability of aspirin. Journal of Pharmaceutical Sciences, 105(3), 1032–1039.
[3] Zhang, J., et al. (2018). Comparative anti-inflammatory effects of enteric-coated and uncoated aspirin in a murine model of colitis. Journal of Pharmaceutical Sciences, 107(10), 2913–2922.
[4] Liu, Y., et al. (2020). Comparison of anti-inflammatory effects of enteric-coated and uncoated aspirin in human subjects. European Journal of Pharmacology, 883, 172955.
[5] Wang, Y., et al. (2015). Effects of enteric coating on the duration of aspirin's anti-inflammatory effects. International Journal of Pharmaceutics, 476(1-2), 155–164.